Results 211 to 220 of about 29,485 (291)

Bispecific Antibodies: Strategies Available to Optimize Their Safe Delivery in Patients with Multiple Myeloma. [PDF]

Antibodies (Basel)
Giles HV, Kishore B.
europepmc   +1 more source

To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies. [PDF]

Front Immunol
Paulsen JS, Slørdahl TS.
europepmc   +1 more source

Immune, molecular and genetic profiles of gastric signet ring cell carcinoma: Recent progress and future challenges

International Journal of Cancer, Volume 159, Issue 1, Page 11-29, 1 July 2026.
Abstract Gastric signet ring cell carcinoma (GSRCC) is a special type of gastric cancer common in young women. Diffuse gastric cancer (DGC) begins with intramucosal lesions comprising differentiated GSRCC cells. Genetically, GSRCC and DGC are clonally identical, with their morphology influenced by extracellular Wnt signaling.
Qian Wang, Shuai Zhou, Xiongchao Fang, Xianli He, Gang Wang, Nan Wang   +5 more
wiley   +1 more source

Outpatient step-up dosing of bispecific antibodies in relapsed or refractory multiple myeloma: an oncology nursing framework for monitoring and supportive care. [PDF]

Front Oncol
Song Y, Zhou X, Wang L.
europepmc   +1 more source

Chemical‐Assembled Macrophage‐Engaging Glypican‐3 × Signal Regulatory Protein‐α (SIRP‐α) Bispecific Antibody for Immunotherapy Against Liver Cancer

MedComm, Volume 7, Issue 7, July 2026.
We developed a novel chemical strategy to generate a glypican‐3 × SIRP‐α bispecific antibody that simultaneously blocks the CD47 “don't eat me” signal, engages macrophages to target liver cancer cells for enhanced phagocytosis, and antigen presentation. This novel combination of targets demonstrates remarkable efficacy in vitro and in vivo.
Bo Tang, Wing Hei Leung, Chihao Shao, Dongfang Li, Kwai Man Lau, Macro K. H. Lui, Jingyi Liu, Jacky C. H. Chu, Clare S. W. Yan, Chi‐Ming Che, Xuechen Li, Wing‐Tak Wong, Larry Ming Cheung Chow, Terence K. W. Lee, Clarence T. T. Wong   +14 more
wiley   +1 more source

Real-world resource utilization, toxicity management, and efficacy outcomes of CD20 × CD3 bispecific antibodies in B-cell lymphoma: A study from the GELTAMO network. [PDF]

Hemasphere
Bastos-Oreiro M, Iacoboni G, Navarro V, Martínez C, Manresa P, Magnano L, Jiménez-Ubieto A, Vázquez S, Rodriguez MJ, Busnego MT, Del Campo R, Paúl PJ, Murillo I, Donato EM, Serna A, Luzardo H, Gómez P, Pérez E, Mendibil B, Ramos S, García-Noblejas A, Gonzalez de Villambrosia S, Díaz FJ, López J, Martín-Moro F, Fernandez-Caldas P, Fernandez R, Gutierrez A, Sánchez B, Domínguez N, Civeira M, Villafuerte P, Olazabal I, Zeberio I, Barrenetxea C, Gutierrez N, Romero S, Martín-Consuegra S, Huerga S, Golbano N, Riaza R, Hueso JA, Martinez-Barranco P, Navarro B, Villalón L, Ortega P, Torres A, Ormenazabal I, Sanchez Anton MP, Goñi MA, Abrisqueta P, Martín García-Sancho A.   +51 more
europepmc   +1 more source

Osimertinib Resistance in EGFR‐Mutated Non–Small Cell Lung Cancer: Mechanisms and Therapeutic Strategies

MedComm, Volume 7, Issue 7, July 2026.
This review illustrates the key mechanisms of osimertinib resistance in EGFR‑mutant NSCLC, including EGFR‑dependent mutations, bypass pathway activation, and SMARCA4‑mediated epigenetic regulation. We also summarize emerging targeted therapies and future perspectives to overcome EGFR‑TKI resistance.
Junfeng Guo, Qiuyuan Wen, Songqing Fan
wiley   +1 more source

Structural stability of symmetric bispecific antibodies: a case study showing potential compromise near linker regions. [PDF]

Sci Rep
Ingavat N, Kok YJ, Dzulkiflie N, Min LJ, Xinhui W, Low KN, But KP, Anajao A, Ping LH, Ong HK, Mahfut FB, Yang Y, Bi X, Zhang W.   +13 more
europepmc   +1 more source

Clonal Hematopoiesis and Type 2 Diabetes: A Narrative Review

Journal of Diabetes, Volume 18, Issue 7, July 2026.
Clonal hematopoiesis (CH), driven by obesity‐ and aging‐related inflammation, may be causally associated with an increased risk of Type 2 diabetes through the inflammation–insulin resistance pathway. By exacerbating systemic inflammation, CH may also contribute to the development of macrovascular and microvascular complications in patients with Type 2 ...
Jian‐Jun Liu, Sylvia Liu, Resham L. Gurung, Su Chi Lim, Rajkumar Dorajoo   +4 more
wiley   +1 more source

Bispecific Antibodies in Hematologic Malignancies: Attacking the Frontline. [PDF]

BioDrugs
Shastri T, Trabolsi A, Arumov A, Schatz JH.   +3 more
europepmc   +1 more source